查詢結果分析
來源資料
頁籤選單縮合
題 名 | 嶄新抗C型肝炎口服藥 Sofosbuvir=New Generation of Oral Anti-HCV Drug--Sofosbuvir |
---|---|
作 者 | 梁高誌; 吳芝瑩; | 書刊名 | 藥學雜誌 |
卷 期 | 30:4=121 2014.12[民103.12] |
頁 次 | 頁44-47 |
分類號 | 415.5332、415.5332 |
關鍵詞 | C型肝炎; RNA病毒; NS5B聚合酶抑製劑; Sofosbuvir; |
語 文 | 中文(Chinese) |
中文摘要 | 根據 WHO 所公布的數據,目前全世界約有1.7億感染C型肝炎 (hepatitis C virus; HCV) 病毒者,而C型肝炎病毒主要是藉由血液、母親垂直傳染給胎兒或是經由性行 為傳染。急性的C型肝炎病毒感染通常無症狀,也不易被發覺,約有85%的病人會轉 為慢性感染,同時20-30%的病人最終會發展成肝硬化,因而增加肝癌發生率。在分 類上C型肝炎病毒屬於黃病毒科 (flaviviridae) 為 RNA 病毒,可再細分為6種基因型, 其中以1~4型較為常見。其基因體會轉譯成一個多蛋白 (polyprotein),經由病毒本身或 是宿主的蛋白酶 (protease) 切割成4個結構蛋白和6個非結構蛋白,其中非結構蛋白包 括NS2, NS3, NS4A, NS4B, NS5A 及 NS5B。Sofosbuvir 的機轉為 HCV nucleotide NS5B 聚合酶抑制劑 (polymerase inhibitor),為第一個不需要合併干擾素給藥即有治療效果 的藥品,對此,本文將針對 sofosbuvir 這個新一代治療C型肝炎藥品從不同的角度做 更進一步的介紹。 |
英文摘要 | According to data published by WHO, there are around 170 million people infected by hepatitis C virus (HCV) mainly through blood, mother vertical transmission to the fetus, or via sexual transmission. Acute HCV infection is usually asymptomatic, not easily found, around 85% of patients are chronic hepatitis C patient, and 20 to 30% patients will eventually develop into cirrhosis, thus increasing the incidence of liver cancer. Classification of HCV is divided to flaviviridae of RNA viruses and further subdivided into six genotypes, type 1 to 4 is more common happened. Its genome is translated into polyprotein, the virus was cut into four structural proteins and six non-structural proteins by itself or the host proteases, the non-structural proteins including NS2, NS3, NS4A, NS4B, NS5A and NS5B. Sofosbuvir is a HCV nucleotide NS5B polymerase inhibitor. It is the first drug without not require combineing with interferon to effectively treat HCV. We will further introduce this new generation of oral anti-HCV sofosbuvir through different ways. |
本系統中英文摘要資訊取自各篇刊載內容。